Loading news...
Of all the retirement activities you can engage in, worrying about your financial security shouldn't be one of them.
JNJ's immunology and neuroscience units are driving growth, with Tremfya, Caplyta and Spravato offsetting Stelara's LOE hit.
Fast Track designation reflects the unmet need in this serious disease and enables the potential for an accelerated FDA review timeline The designation is supported by a Phase 2 study in which nipocalimab demonstrated reduction in lupus disease activity and potential for steroid sparing Systemic lupus erythematosus is a debilitating, chronic autoantibody-driven disease affecting multiple organs, with limited treatment options and risk of irreversible organ damage Johnson & Johnson is actively enrolling patients in a Phase 3 study of adults with active systemic lupus erythematosus SPRING HOUSE, Pa., March 3, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that nipocalimaba was granted U.S. Food and Drug Administration (FDA) Fast Track designation as a potential treatment for adults with systemic lupus erythematosus (SLE), a debilitating autoantibody-driven disease that impacts approximately 3 to 5 million people worldwide.1 The U.S. FDA's Fast Track designation program is designed to expedite the development and review timelines of drugs that demonstrate the potential to treat serious conditions, aiming to deliver therapeutics to patients more quickly in areas, like SLE, where unmet needs remain.2 "Nipocalimab earning its fifth FDA Fast Track designation, now in systemic lupus erythematosus, reflects the importance of accelerating the delivery of an immunoselective therapy that could fill an unmet need in this serious condition," said Leonard L.
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, April 14th to review first-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Darren Snellgrove, Vice President, Investor Relations will host the call. The question and answer portion of the call will also include additional members of Johnson & Joh.
AbbVie says 55% of Crohn's patients reached remission in a late-stage study, boosting Skyrizi's outlook amid market competition.
In the Large-Cap Pharmaceuticals industry, Lilly, J&J, BAYRY and Sanofi are worth retaining as the industry shows some recovery.
Davis R M Inc. decreased its holdings in shares of Johnson and Johnson (NYSE: JNJ) by 1.4% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 215,437 shares of the company's stock after selling 3,013 shares during the quarter. Davis
Aprio Wealth Management LLC grew its stake in shares of Johnson and Johnson (NYSE: JNJ) by 36.0% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 11,783 shares of the company's stock after purchasing an additional 3,117 shares during the quarter.
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.
American Century Companies Inc. decreased its position in Johnson and Johnson (NYSE: JNJ) by 33.5% in the undefined quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 4,481,285 shares of the company's stock after selling 2,260,510 shares during the period. Johnson and Johnson accounts for
Banco Santander S.A. decreased its holdings in shares of Johnson and Johnson (NYSE: JNJ) by 4.1% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 52,366 shares of the company's stock after selling 2,266 shares during the quarter. Banco
Johnson & Johnson (JNJ) closed the most recent trading day at $248.43, moving +2.04% from the previous trading session.
Johnson & Johnson's JNJ stock has risen 38.4% in the past six months. The stock has also been trading above its 50-day and 200-day simple moving averages (SMAs) for more than eight months since mid-June 2025 due to its positive earnings outlook and improving fundamentals.
DNB Asset Management AS cut its holdings in shares of Johnson and Johnson (NYSE: JNJ) by 7.6% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,161,215 shares of the company's stock after selling 94,911 shares during the period. Johnson and Johnson
Johnson & Johnson's diversified healthcare business can thrive even in a downturn. The company's outstanding dividend program can help offset market losses.
Andra AP fonden lowered its position in Johnson and Johnson (NYSE: JNJ) by 3.4% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 201,600 shares of the company's stock after selling 7,100 shares during the period. Andra AP fonden's
We are looking at a screening process to sort out and look for some potential opportunities in the elite group known as the dividend kings. Dividend growers can help investors combat the erosion of buying power caused by inflation and combat potential dividend cuts, to help continue to grow longer-term cash flow. Today, we are looking at 25 opportunities, but more specifically at 2 different names as interesting names worth investors' attention.
Combination demonstrates deep PSA responses and favorable safety profile with plans to advance into Phase 3 Data highlight the potential of this first-in-class next-generation T-cell engager to expand the role of immunotherapy in prostate cancer RARITAN, N.J., Feb. 26, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced preliminary results from a Phase 1b study evaluating pasritamig (JNJ-78278343), a first-in-class bispecific T-cell engaging antibody, in combination with docetaxel in patients with metastatic castration-resistant prostate cancer.
AlphaCore Capital LLC lifted its position in Johnson and Johnson (NYSE: JNJ) by 20.2% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 31,848 shares of the company's stock after acquiring an additional 5,343 shares during the quarter. AlphaCore
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?